Company intelligence / Profile preview

UmanDiagnostics

Umeå, Sweden

Ownership: Private
Development stage: Other

Overview

UmanDiagnostics, now a division of Quanterix, provides highly specific monoclonal antibody-based ELISA kits for the detection of neurofilament light protein, enabling sensitive and early diagnosis of neurodegenerative diseases. The platform is widely acknowledged in academia and industry, with close to 400 citations in peer-reviewed publications

Therapeutic areas: Neurology
Modalities: ProteinMonoclonal antibodyELISA-based diagnostic
Industry: Protein Biomarker Diagnostics

Partnerships

Bio-Techne (license/supply agreement for Nf-L antibodies for immunoassay platforms)EATRIS (collaboration support for academic/industry partnerships)

Beyond the preview

Go deeper on UmanDiagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UmanDiagnostics.

Explore the full profile